25 Mg Tegoprazan Composition for Long-Term GERD Recurrence Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for gastroesophageal reflux disease (GERD) fail to effectively prevent recurrence, with a high recurrence rate despite the use of gastric-acid secretion inhibitors, and may worsen symptoms or cause complications, necessitating a safer and more effective prevention method.

Innovation Solution

A pharmaceutical composition containing tegoprazan or its pharmaceutically acceptable salt in a 25mg dose is administered to prevent the recurrence of GERD, showing stability and efficacy without side effects, unaffected by H. pylori infection or CYP gene polymorphism.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If gastric-acid secretion inhibitors are administered to treat GERD, then symptoms are relieved, but recurrence occurs in 60-70% of patients within a certain period

Engineering Contradiction:

Improveprevention of GERD recurrenceVSAvoidduration of symptom relief

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent employs parameter changes by switching from conventional gastric-acid secretion inhibitors to tegoprazan, a novel compound with modified chemical structure and pharmacological properties. Tegoprazan demonstrates sustained acid suppression efficacy with a unique mechanism of action that targets the H+/K+-ATPase enzyme differently, providing longer-lasting symptom relief and preventing recurrence in patients who previously experienced relapse within 60-70% recurrence rate

Inventive Principle:

Principle #35Parameter changes

2Reliability

If the same dose of gastric-acid secretion inhibitor is administered upon recurrence, then treatment is maintained, but effect is reduced or symptoms worsen

Engineering Contradiction:

Improveconsistency of treatment effectVSAvoidefficacy of repeated treatment

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies inversion by using tegoprazan instead of conventional gastric-acid secretion inhibitors for maintenance therapy. This approach reverses the treatment strategy by employing a different class of medication with a novel mechanism of action, which effectively prevents recurrence and maintains consistent treatment effect without the diminishing returns observed with repeated use of conventional inhibitors

Inventive Principle:

Principle #13The other way round (Inversion)

3Duration of action of stationary object

If long-term treatment is administered to prevent recurrence, then symptom relief is maintained, but side effects may occur

Engineering Contradiction:

Improveduration of symptom reliefVSAvoidside effects

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent applies this principle by using tegoprazan as a maintenance therapy that can be administered periodically to prevent recurrence. The compound provides sustained protection against GERD recurrence with a favorable side effect profile, allowing long-term use without significant adverse effects. The treatment approach balances duration of action with safety, enabling patients to maintain symptom relief over extended periods

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentEP3927340B1Pharmaceutical composition comprising tegoprazan for preventing the recurrence of gastroesophageal reflux disease

Publication Date: 2025.09.03 HK INNO N CORP

Figure 1

AI summary

The present invention relates to a pharmaceutical composition for preventing the recurrence of gastroesophageal reflux disease, comprising a benzimidazole derivative. The pharmaceutical composition of the present invention may effectively prevent the recurrence of gastroesophageal reflux disease without any side effects for a long period of time.